ATE334693T1 - Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten - Google Patents
Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheitenInfo
- Publication number
- ATE334693T1 ATE334693T1 AT03712535T AT03712535T ATE334693T1 AT E334693 T1 ATE334693 T1 AT E334693T1 AT 03712535 T AT03712535 T AT 03712535T AT 03712535 T AT03712535 T AT 03712535T AT E334693 T1 ATE334693 T1 AT E334693T1
- Authority
- AT
- Austria
- Prior art keywords
- treatment
- tyrosine kinase
- kinase inhibitors
- cns diseases
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35965202P | 2002-02-27 | 2002-02-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE334693T1 true ATE334693T1 (de) | 2006-08-15 |
Family
ID=27766120
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT03712535T ATE334693T1 (de) | 2002-02-27 | 2003-02-26 | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten |
Country Status (12)
Country | Link |
---|---|
US (2) | US20050222091A1 (de) |
EP (1) | EP1478380B1 (de) |
JP (1) | JP2005526048A (de) |
AT (1) | ATE334693T1 (de) |
AU (1) | AU2003216625A1 (de) |
CA (1) | CA2477111A1 (de) |
CY (1) | CY1105577T1 (de) |
DE (1) | DE60307237T2 (de) |
DK (1) | DK1478380T3 (de) |
ES (1) | ES2269994T3 (de) |
PT (1) | PT1478380E (de) |
WO (1) | WO2003072090A2 (de) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7700610B2 (en) | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
ATE330608T1 (de) * | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
WO2003004007A2 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
CA2452368A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
WO2003004006A2 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
DE60228278D1 (de) * | 2001-09-20 | 2008-09-25 | Ab Science | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung |
DE60227701D1 (de) * | 2001-09-20 | 2008-08-28 | Ab Science | Die verwendung von c-kithemmern zur förderung des haarwuchses |
US20060128720A1 (en) * | 2002-03-21 | 2006-06-15 | Kufe Donald W | Inhibition of cell death responses induced by oxidative stress |
BRPI0415467A (pt) | 2003-10-23 | 2006-12-19 | Ab Science | compostos de 2-aminoariloxazol para o tratamento de doenças |
WO2005102318A1 (en) * | 2004-04-20 | 2005-11-03 | Ab Science | Use of c-kit inhibitors for treating hiv related diseases |
US20100316626A1 (en) * | 2006-08-11 | 2010-12-16 | The Government Of The United States Of America As Represented By The Secretary | Methods for treatment and diagnosis of psychiatric disorders |
CN101657446B (zh) | 2007-02-13 | 2013-05-15 | Ab科学有限公司 | 合成作为激酶抑制剂的2-氨基噻唑化合物的方法 |
WO2008121346A1 (en) * | 2007-03-30 | 2008-10-09 | Massachusetts Institute Of Technology | Methods for identifying compounds that modulate neurotrophic factor signaling |
WO2008145789A1 (es) * | 2007-05-28 | 2008-12-04 | Pontificia Universidad Catolica De Chile | Uso de compuestos derivados de benzamidina metanosulfonato o su sal farmacéuticamente aceptable, por ejemplo mesilato de imatinib, para preparar un medicamento para el tratamiento de la enfermedad neurodegenerativa de niemann pick de tipo c ( npc). |
EP2068152A1 (de) * | 2007-12-06 | 2009-06-10 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | c-Kit als neuartiges Target zur Schmerzbehandlung |
TW201102068A (en) * | 2009-06-02 | 2011-01-16 | Novartis Ag | Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms |
EP2844256B1 (de) * | 2012-05-02 | 2023-02-22 | Georgetown University | Behandlung der Amyotrophen Lateralsklerose mit Tyrosinkinasehemmern |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3558653A (en) * | 1968-05-20 | 1971-01-26 | Searle & Co | Dialkylaminoalkyl-indolines |
US3725403A (en) * | 1970-10-20 | 1973-04-03 | Squibb & Sons Inc | Benzothiazine derivatives |
US5521184A (en) * | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
TW225528B (de) * | 1992-04-03 | 1994-06-21 | Ciba Geigy Ag | |
US5880141A (en) * | 1995-06-07 | 1999-03-09 | Sugen, Inc. | Benzylidene-Z-indoline compounds for the treatment of disease |
GB9523675D0 (en) * | 1995-11-20 | 1996-01-24 | Celltech Therapeutics Ltd | Chemical compounds |
US6114371A (en) * | 1997-06-20 | 2000-09-05 | Sugen, Inc. | 3-(cyclohexanoheteroarylidenyl)-2-indolinone protein tyrosine kinase inhibitors |
US6133305A (en) * | 1997-09-26 | 2000-10-17 | Sugen, Inc. | 3-(substituted)-2-indolinones compounds and use thereof as inhibitors of protein kinase activity |
US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
AU4204099A (en) * | 1998-05-27 | 1999-12-13 | Sherwood L. Gorbach | Isoflavonoids for treatment and prevention of migraine headaches |
US6498165B1 (en) * | 1999-06-30 | 2002-12-24 | Merck & Co., Inc. | Src kinase inhibitor compounds |
US6762180B1 (en) * | 1999-10-13 | 2004-07-13 | Boehringer Ingelheim Pharma Kg | Substituted indolines which inhibit receptor tyrosine kinases |
DE60029138T2 (de) * | 1999-12-22 | 2007-06-06 | Sugen, Inc., San Francisco | Verwendung von Indolinonverbindungen zur Herstellung von Pharmazeutika für die Modulation der Funktion c-kit Proteintyrosinkinase |
AU3704101A (en) * | 2000-02-17 | 2001-08-27 | Amgen Inc | Kinase inhibitors |
AU1826202A (en) * | 2000-10-27 | 2002-05-06 | Novartis Ag | Treatment of gastrointestinal stromal tumors |
EP1721609A3 (de) * | 2001-05-16 | 2007-01-31 | GPC Biotech AG | Pyridylpyrimidinderivate als effektive Verbindungen gegen Prioninfektionen und prion Erkrankungen |
JP2004530722A (ja) * | 2001-06-29 | 2004-10-07 | アブ サイエンス | 骨喪失を治療するためのチロシンキナーゼ阻害剤の使用法 |
CA2452368A1 (en) * | 2001-06-29 | 2003-01-09 | Ab Science | New potent, selective and non toxic c-kit inhibitors |
WO2003004006A2 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of potent, selective and non toxic c-kit inhibitors for treating tumor angiogenesis |
WO2003004007A2 (en) * | 2001-06-29 | 2003-01-16 | Ab Science | Use of tyrosine kinase inhibitors for treating inflammatory bowel diseases (ibd) |
US20030091974A1 (en) * | 2001-06-29 | 2003-05-15 | Alain Moussy | Method for screening compounds capable of depleting mast cells |
JP2005502614A (ja) * | 2001-06-29 | 2005-01-27 | アブ サイエンス | 多発性硬化症(ms)を治療するためのチロシンキナーゼ阻害剤の使用方法 |
JP2005503361A (ja) * | 2001-06-29 | 2005-02-03 | アブ サイエンス | 肥満細胞症治療のための強力で選択的かつ非毒性のc−kit阻害剤の使用 |
US7700610B2 (en) * | 2001-06-29 | 2010-04-20 | Ab Science | Use of tyrosine kinase inhibitors for treating allergic diseases |
ATE330608T1 (de) * | 2001-06-29 | 2006-07-15 | Ab Science | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen |
ATE401079T1 (de) * | 2001-06-29 | 2008-08-15 | Ab Science | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen |
WO2003039550A1 (en) * | 2001-09-20 | 2003-05-15 | Ab Science | Use of tyrosine kinase inhibitors for whitening human skin and treating melanocyte dysfunction associated diseases |
DE60227701D1 (de) * | 2001-09-20 | 2008-08-28 | Ab Science | Die verwendung von c-kithemmern zur förderung des haarwuchses |
US20040241226A1 (en) * | 2001-09-20 | 2004-12-02 | Alain Moussy | Use of potent, selective and non-toxic c-kit inhibitors for treating bacterial infections |
DE60228278D1 (de) * | 2001-09-20 | 2008-09-25 | Ab Science | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung |
IL162838A0 (en) * | 2002-01-04 | 2005-11-20 | Univ Rockefeller | Compositions and methods for prevention and treatment peptide-of amyloid- related disorders |
US20050089838A1 (en) * | 2002-06-28 | 2005-04-28 | Alain Moussy | Method for identifying compounds that specifically deplete mast cells |
WO2004062591A2 (en) * | 2003-01-06 | 2004-07-29 | Oregon Health And Science University | Methods of treatment and diagnosis of kaposi's sarcoma (ks) and ks related diseases |
-
2003
- 2003-02-26 CA CA002477111A patent/CA2477111A1/en not_active Abandoned
- 2003-02-26 AU AU2003216625A patent/AU2003216625A1/en not_active Abandoned
- 2003-02-26 DK DK03712535T patent/DK1478380T3/da active
- 2003-02-26 JP JP2003570836A patent/JP2005526048A/ja active Pending
- 2003-02-26 PT PT03712535T patent/PT1478380E/pt unknown
- 2003-02-26 AT AT03712535T patent/ATE334693T1/de not_active IP Right Cessation
- 2003-02-26 WO PCT/IB2003/001425 patent/WO2003072090A2/en active IP Right Grant
- 2003-02-26 US US10/505,842 patent/US20050222091A1/en not_active Abandoned
- 2003-02-26 EP EP03712535A patent/EP1478380B1/de not_active Expired - Lifetime
- 2003-02-26 ES ES03712535T patent/ES2269994T3/es not_active Expired - Lifetime
- 2003-02-26 DE DE60307237T patent/DE60307237T2/de not_active Expired - Lifetime
-
2006
- 2006-09-04 CY CY20061101257T patent/CY1105577T1/el unknown
-
2008
- 2008-08-13 US US12/191,149 patent/US20090082360A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE60307237T2 (de) | 2007-10-18 |
DK1478380T3 (da) | 2006-11-27 |
WO2003072090A2 (en) | 2003-09-04 |
CA2477111A1 (en) | 2003-09-04 |
PT1478380E (pt) | 2006-12-29 |
AU2003216625A1 (en) | 2003-09-09 |
CY1105577T1 (el) | 2010-07-28 |
US20090082360A1 (en) | 2009-03-26 |
EP1478380A2 (de) | 2004-11-24 |
US20050222091A1 (en) | 2005-10-06 |
JP2005526048A (ja) | 2005-09-02 |
WO2003072090A3 (en) | 2003-11-13 |
ES2269994T3 (es) | 2007-04-01 |
DE60307237D1 (de) | 2006-09-14 |
EP1478380B1 (de) | 2006-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60307237D1 (de) | Verwendung von tyrosine-kinase inhibitoren zur behandlung von cns krankheiten | |
ATE404202T1 (de) | Die verwendung von potenten, selektiven und nontoxischen c-kithemmern zur behandlung von interstitieller blasenentzündung | |
ATE395052T1 (de) | Verwendung von c-kit-inhibitoren für die behandlung von typ-2-diabetes | |
MXPA05001277A (es) | 2-(3-aminoaril)amino-4-aril-tiazoles y su uso como inhibidores del c-kit. | |
WO2003002114A3 (en) | Use of potent, selective and non toxic c-kit inhibitors for treating mastocytosis | |
DE60227709D1 (de) | Die verwendung von c-kithemmern zur behandlung von autoimmunerkrankungen | |
ATE330608T1 (de) | Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen | |
GEP20053631B (en) | ) New Spirotricyclic Derivatives and Their Use as Phosphodiesterase-7 Inhibitors | |
ATE345839T1 (de) | Die verwendung von tyrosinkinasehemmer zur behandlung von allergischen erkrankungen | |
ATE452642T1 (de) | Verwendung von cox-2 inhibitoren zur behandlung von affectiven störungen | |
WO2003002107A3 (en) | Use of tyrosine kinase inhibitors for treating multiple sclerosis (ms) | |
ATE388711T1 (de) | C-kithemmer zur behandlung von bakteriellen infektionen | |
ATE343415T1 (de) | Die verwendung von c-kit hemmer zur behandlung von entzündlichen darmerkrankungen | |
ATE260653T1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
WO2003002105A3 (en) | Use of tyrosine kinase inhibitors for treating bone loss | |
ATE401078T1 (de) | Die verwendung von c-kithemmern zur förderung des haarwuchses | |
WO2004096225A3 (en) | Use of tyrosine kinase inhibitors for treating cerebral ischemia | |
DE60323613D1 (de) | Verwendung von tyrosinkinase-hemmern zur behandlung von erkrankungen im zusammenhang mit substanzgebrauch | |
DE60220825D1 (de) | Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks | |
DE60209886D1 (de) | Tie2 rezeptor-kinase-inhibitoren zur behandlung von angiogenen erkrankungen | |
ATE409469T1 (de) | Verwendung von 2,2,3,3, tetramethylcyclopropane carbonsäure derivaten zur behandlung von psychiatrischen störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
UEP | Publication of translation of european patent specification |
Ref document number: 1478380 Country of ref document: EP |
|
REN | Ceased due to non-payment of the annual fee |